Highlights | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Views 1,234
Citations 0
In This Issue of JAMA Dermatology
July 2014


JAMA Dermatol. 2014;150(7):685. doi:10.1001/jamadermatol.2013.6545

Pemphigus is a rare and potentially fatal autoimmune dermatologic disease that often requires long-term systemic treatment with corticosteroids or other immunosuppressive agents. Rituximab, a chimeric murine/human monoclonal antibody that induces B-cell apoptosis by targeting CD20 antigen, has been reported to effectively treat autoimmune bullous dermatoses. Optimal dosage regimens have not been determined. In this retrospective cohort study, Heelan et al demonstrate that a fixed-dose modified rheumatoid arthritis protocol for rituximab was effective and well tolerated by patients with pemphigus. These data suggest that rituximab may be considered as first-line therapy for autoimmune bullous disorders.

Mycosis fungoides and Sézary syndrome (MF/SS) are uncommon in children and young adults and have distinct clinical features, such as higher proportion of early-stage disease and superior disease-specific survival. In this population-based study, Weiyun et al demonstrate that although young patients with MF/SS were at elevated risk of second cancers (particularly melanoma and lymphoma), they generally had a favorable outcome. Continual monitoring of young patients with MF/SS may determine whether this risk is due to increased medical surveillance, long-term treatment, or underlying disease processes.